Novo Nordisk Rallies 3.6% as Hims & Hers Pulls Compounded Semaglutide
ZACKS·2026-02-10 13:16

Key Takeaways Novo Nordisk shares rose 3.6% after a rival halted compounded semaglutide sales.An FDA warning flagged safety and compliance issues for compounded semaglutide versus NVO's Wegovy.A patent lawsuit shows Novo Nordisk defending IP to protect pricing power and market share in obesity drugs.Shares of Novo Nordisk A/S (NVO) jumped 3.6% after Hims & Hers Health, Inc. (HIMS) announced it would halt sales of its compounded semaglutide pill, following an FDA warning and a patent lawsuit filed by NVO, a ...